Related Experiment Video
Updated: Aug 6, 2026
In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones
Published on: July 25, 2019
The Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic
Jiaojiao Hong1,2, Xianzi Dai1,2, Jiangxia Yuan1,2
1The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Background:
Malignant pleural mesothelioma (MPM) originates from pleural mesothelial cells and represents a highly aggressive malignancy. Characterized by a prolonged latency period, poor survival prognosis, and non-specific clinical manifestations, MPM poses significant diagnostic and therapeutic challenges. BRCA-1-associated protein 1 (BAP1) is a nuclear deubiquitinating enzyme involved in chromatin regulation, homologous recombination, and programmed cell death. Although multiple studies have suggested that BAP1 loss or mutation holds prognostic significance in malignant pleural mesothelioma, this remains a matter of debate.
Methods:
A meta-analysis was conducted using data from the Web of Science, PubMed, Embase, Cochrane, and CNKI up to October 21, 2025. We included studies involving patients with malignant pleural mesothelioma that assessed the prognostic significance of BAP1. These studies reported hazard ratios (HR) and 95% confidence intervals (CI) for median overall survival (mOS) and median progression-free survival (mPFS).
Results:
A total of 14 articles meeting the inclusion criteria were identified, encompassing 1,835 patients. We conducted both univariate and multivariate analyses of mOS, revealing that BAP1 deletion or mutation consistently correlated with improved prognosis, with hazard ratios of 0.51 (95% CI, 0.45-0.58, P < 0.0001) and 0.62 (95% CI, 0.54-0.71, P < 0.0001), respectively. The values were statistically significant (P < 0.0001). Furthermore, analyses of mPFS continued to demonstrate that BAP1 deletion or mutation consistently correlated with improved prognosis (U: HR = 0.62, 95% CI = 0.39-0.99, P = 0.04; M: HR = 0.79, 95% CI = 0.51-1.24, P = 0.31), though this did not reach statistical significance. Sensitivity analyses confirmed the robustness of these findings, with minimal heterogeneity between studies.
Conclusion:
BAP1 serves as a potential prognostic marker for MPM, with its deletion or mutation indicating a favourable prognosis for patients. However, whether it provides valuable insights for various treatment strategies, including immunotherapy, requires further clinical investigation to determine.
Insights
Loss or mutation of BRCA-1-associated protein 1 (BAP1) in malignant pleural mesothelioma (MPM) is linked to a better prognosis. This meta-analysis confirms BAP1 as a potential prognostic marker for MPM patients.
Area of Science:
- Oncology
- Genetics
- Biomarkers
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis.
- BRCA-1-associated protein 1 (BAP1) is a nuclear enzyme involved in DNA repair and cell death.
- The prognostic significance of BAP1 alterations in MPM is debated.
Purpose of the Study:
- To conduct a meta-analysis to evaluate the prognostic significance of BAP1 loss or mutation in MPM.
- To consolidate evidence regarding the association between BAP1 status and patient survival outcomes.
Main Methods:
- A comprehensive meta-analysis was performed using data from multiple databases (Web of Science, PubMed, Embase, Cochrane, CNKI).
- Studies assessing BAP1 prognostic significance in MPM patients were included.
- Hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS) were extracted and analyzed.
Main Results:
- 14 articles with 1,835 patients were included.
- BAP1 deletion or mutation significantly correlated with improved overall survival (HR=0.51 for univariate, HR=0.62 for multivariate analyses; P < 0.0001).
- BAP1 alterations showed a trend towards improved progression-free survival, though not statistically significant in all analyses.
Conclusions:
- BAP1 deletion or mutation is a significant favorable prognostic marker in malignant pleural mesothelioma.
- Further clinical research is warranted to explore BAP1's role in treatment strategies, including immunotherapy.
